Latest period
$32.85B
YoY change
-8.4%
5Y CAGR
-6.2%
Peak year (2020)
$50.19B
Latest annual
$36.41B
Total Liabilities history chart for Gilead Sciences (GILD) from 1990 to 2025
Latest: $36.41B
Total Liabilities growth chart for Gilead Sciences (GILD) from 1990 to 2025
Latest: -8.4%
Total Liabilities history table for Gilead Sciences (GILD) from 1990 to 2025
| 2025 | $36.41B | -8.4% | −$3.34B | ||
| 2024 | $39.75B | +0.9% | +$373.00M | ||
| 2023 | $39.38B | -6.2% | −$2.59B | ||
| 2022 | $41.96B | -10.5% | −$4.93B | ||
| 2021 | $46.89B | -6.6% | −$3.30B | ||
| 2020 | $50.19B | +28.8% | +$11.21B | ||
| 2019 | $38.98B | -7.5% | −$3.16B | ||
| 2018 | $42.14B | -15.3% | −$7.64B | ||
| 2017 | $49.78B | +32.3% | +$12.17B | ||
| 2016 | $37.61B | +15.4% | +$5.01B | ||
| 2015 | $32.60B | +73.0% | +$13.76B | ||
| 2014 | $18.84B | +73.9% | +$8.01B | ||
| 2013 | $10.83B | -7.4% | −$862.12M | ||
| 2012 | $11.70B | +12.1% | +$1.26B | ||
| 2011 | $10.44B | +90.8% | +$4.96B | ||
| 2010 | $5.47B | +71.3% | +$2.28B | ||
| 2009 | $3.19B | +29.2% | +$722.15M | ||
| 2008 | $2.47B | +10.6% | +$236.82M | ||
| 2007 | $2.23B | +0.8% | +$17.25M | ||
| 2006 | $2.22B | +200.2% | +$1.48B | ||
| 2005 | $738.54M | +159.1% | +$453.45M | ||
| 2004 | $285.09M | -48.3% | −$266.66M | ||
| 2003 | $551.75M | -23.0% | −$165.09M | ||
| 2002 | $716.84M | +109.4% | +$374.49M | ||
| 2001 | $342.35M | +4.7% | +$15.37M | ||
| 2000 | $326.98M | +134.4% | +$187.46M | ||
| 1999 | $139.52M | -9.5% | −$14.58M | ||
| 1998 | $154.10M | +342.8% | +$119.30M | ||
| 1997 | $34.80M | +83.2% | +$15.80M | ||
| 1996 | $19.00M | +25.0% | +$3.80M | ||
| 1995 | $15.20M | -6.7% | −$1.10M | ||
| 1994 | $16.30M | — | — | ||
| 1992 | $7.40M | +138.7% | +$4.30M | ||
| 1991 | $3.10M | +34.8% | +$800.00K | ||
| 1990 | $2.30M | — | — |
- 2025$36.41B-8.4%
- 2024$39.75B+0.9%
- 2023$39.38B-6.2%
- 2022$41.96B-10.5%
- 2021$46.89B-6.6%
- 2020$50.19B+28.8%
- 2019$38.98B-7.5%
- 2018$42.14B-15.3%
- 2017$49.78B+32.3%
- 2016$37.61B+15.4%
- 2015$32.60B+73.0%
- 2014$18.84B+73.9%
- 2013$10.83B-7.4%
- 2012$11.70B+12.1%
- 2011$10.44B+90.8%
- 2010$5.47B+71.3%
- 2009$3.19B+29.2%
- 2008$2.47B+10.6%
- 2007$2.23B+0.8%
- 2006$2.22B+200.2%
- 2005$738.54M+159.1%
- 2004$285.09M-48.3%
- 2003$551.75M-23.0%
- 2002$716.84M+109.4%
- 2001$342.35M+4.7%
- 2000$326.98M+134.4%
- 1999$139.52M-9.5%
- 1998$154.10M+342.8%
- 1997$34.80M+83.2%
- 1996$19.00M+25.0%
- 1995$15.20M-6.7%
- 1994$16.30M—
- 1992$7.40M+138.7%
- 1991$3.10M+34.8%
- 1990$2.30M—
Total Liabilities values are taken from Gilead Sciences's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Gilead Sciences (GILD)
According to Gilead Sciences's latest reported financial statements, the company's latest reported total liabilities is $32.85B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total liabilities for Gilead Sciences (GILD) came in at $36.41B – declined 8.4% year-over-year.
Through 2020–2025 (5 years), Gilead Sciences total liabilities delivered a -6.2% annualised rate; with a net decline across the window.
2020 marks the peak total liabilities at $50.19B, with the historical low of $2.30M recorded in 1990.
Gilead Sciences Total Liabilities by Year
Gilead Sciences Total Liabilities 2025: $36.41B
Gilead Sciences posted total liabilities of $36.41B in 2025, declined 8.4% below 2024.
Gilead Sciences Total Liabilities 2024: $39.75B
In 2024, Gilead Sciences reported total liabilities of $39.75B, edged up 0.9% from 2023.
Gilead Sciences Total Liabilities 2023: $39.38B
Gilead Sciences total liabilities in 2023 was $39.38B, declined 6.2% below 2022.
Gilead Sciences Total Liabilities 2022: $41.96B
2022's total liabilities for Gilead Sciences came in at $41.96B, declined 10.5% below 2021.
Gilead Sciences Total Liabilities 2021: $46.89B
Gilead Sciences total liabilities in 2021 was $46.89B.
See more financial history for Gilead Sciences (GILD).
Sector peers by Total Liabilities
Healthcare peers of Gilead Sciences (GILD), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Gilead Sciences (GILD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation